FTI Falls After Earnings as Shorts Build and Options Stay Cautious
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
TechnipFMC reported Q3 results on October 29 and fell nearly 4% on the day, closing the week down 1.6% at $68.77, even as several oilfield services peers posted solid gains.
The earnings reaction is the week's defining event. The stock dropped 3.7% on the print, a sharp contrast to peers: HP rose 10.4% on the week, NOV fell 2.4%, and Noble gained 2.7%. FTI has now lagged the sector on both the pre-earnings setup and the post-earnings response. The next quarterly event is not until February 18, 2027, leaving the stock to trade on sentiment and positioning for the next three and a half months.
Short sellers have been rebuilding into the result. Short interest climbed 13% over the week to 3.7% of free float, and is up more than 51% over the past month. That is a meaningful acceleration from a standing start: as recently as early October, short interest was below 2.5% of float. The ORTEX short score has ticked up alongside it, rising from 37.5 on October 23 to 40.7 by October 29. The borrow market is not under any pressure. Availability runs near 2,059% of short interest, well above the 52-week trough of 771%, and borrowing costs remain low at around 0.5%. The short build looks deliberate rather than opportunistic, building in front of a catalyst that has now passed.
Options positioning stayed defensive through the print and has not unwound. The put/call ratio is at 0.39, about one standard deviation above its 20-day average of 0.33, and close to the 52-week high of 0.45. That ratio was below 0.25 as recently as the first week of October. The hedging demand that built into earnings has not rotated out, which suggests some investors remain cautious even after the result is known.
The Street is broadly constructive but trimming targets at the margin. Barclays maintained its Overweight rating on October 15 but cut its price target by $1 to $86. UBS initiated coverage at Buy with an $89 target on October 13. Those two moves bookend the week's analyst activity and both point the same direction: positive on the business, less excited about the near-term entry. The consensus mean target is $76.82, around 12% above Friday's close, which on paper represents solid upside but feels less compelling after a year in which the stock was up nearly 60% at its peak. Valuation has compressed slightly: the PE multiple has fallen about 0.6 points over the past month to 18.9. The analyst recommendation differential factor ranks in the 92nd percentile, the highest single factor score in the matrix, reflecting how lopsided the bull-side coverage remains.
Two details from the corporate activity log are worth noting. On October 27, the CEO Douglas Pferdehirt and CFO Alf Melin both filed tax-withholding transactions coded "F," the standard share-surrender to cover taxes on vesting awards rather than open-market selling. The day before, both received large equity grants coded "A." Neither move is a discretionary signal. The 90-day net share count is essentially flat at 365 shares. Retail attention, measured by Wikipedia page views, is running at a z-score of 2.3 against the prior 90 days, an elevated reading that may reflect the earnings coverage cycle.
What to watch next is whether the short interest build that preceded earnings continues now the result has cleared, or whether those positions are covered as the stock digests the reaction.
Stocks in this article
See the live data behind this article on ORTEX.
Open FTI on ORTEX →How this article was generated
- Generated
- 31 Oct 2026, 20:48
- Data as of
- 31 Oct 2026, 20:48
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.